Investigation and Management of Renal Stone Disease

Holly R. Mabillard; Charles R. V. Tomson


Nephrol Dial Transplant. 2017;32(12):1984-1986. 

In This Article

Abstract and Introduction


Management of nephrolithiasis constitutes a small fraction of the training of most nephrologists, but when done well it can be highly satisfying and—even though the randomized controlled trial (RCT) evidence base is small—intellectually rewarding. The majority of patients who pass a kidney stone are not referred for metabolic evaluation, and that is the way it should be: although up to 75% of stone formers will have a recurrence within 25 years, 25 years is a long time to be restricting diet or taking tablets. So the patients who merit evaluation are those with early-onset or recurrent disease.[1–3]